JUUL E-Cigarette Teen Addiction Lawsuit MDL 2913: Settlement, Claims & 2026 Update
How JUUL Became a Public Health Crisis — and a Legal Reckoning
When JUUL launched in 2015, it looked like a sleek USB drive. It came in fruit and mint flavors. It hit social media with young influencers. It spread through American high schools at a speed that public health officials described as epidemic.
What made JUUL different from prior e-cigarettes was not just design — it was chemistry. JUUL’s patented nicotine salt formulation, using propionic acid to convert freebase nicotine into a salt form, allowed the company to pack roughly 59 milligrams of nicotine per milliliter into a product small enough to fit in a pocket. One pod equaled roughly a pack of cigarettes in nicotine content. And critically, the salt formulation reduced the throat irritation that would normally signal to a user that they were consuming too much nicotine.
For adolescents — whose developing brains are particularly susceptible to nicotine’s addictive effects — JUUL created a nicotine delivery system that was effective, discreet, and deeply addictive before many users understood what was happening.
By 2018–2019, approximately one in four high school seniors reported past-month e-cigarette use, with JUUL commanding the dominant market share. The CDC and FDA declared a “youth vaping epidemic.”
The litigation followed. MDL 2913 consolidated thousands of lawsuits and resulted in settlements exceeding $3.3 billion across multiple agreements. This guide explains what happened, who qualified, and what options remain for those who have not yet pursued claims.
This article is for informational purposes only and does not constitute legal advice.
MDL 2913: Court, Parties, and Current Status
MDL 2913 at a Glance:
| Field | Detail |
|---|---|
| Full case name | In re: JUUL Labs, Inc., Marketing, Sales Practices, and Products Liability Litigation |
| Case number | 3:19-md-02913 |
| Court | U.S. District Court, Northern District of California (N.D. Cal.) |
| Presiding judge | Hon. William H. Orrick |
| Current status | Major settlements complete; some opt-out individual litigation ongoing (2026) |
Defendants:
- JUUL Labs, Inc. — primary manufacturer and marketer
- Altria Group, Inc. — former approximately 35% stakeholder; alleged to have provided marketing and operational support
The Settlements: Verified Figures and Their Scope
The JUUL litigation produced a series of separate settlements negotiated with different plaintiff groups. Each covers different types of claims.
| Settlement | Date | Amount | Plaintiff Group |
|---|---|---|---|
| State AG settlement | September 2022 | ~$438.5 million | 33 states + Puerto Rico AGs |
| Personal injury/consumer aggregate | December 2022 | ~$1.7 billion | ~10,000 personal injury, consumer, government claims |
| School district settlement | April 2023 | ~$1.2 billion | ~1,600 school districts |
| New York AG settlement | Separate | $462 million | New York consumers and youth |
Important caveats:
- The $1.7 billion and $1.2 billion figures represent aggregate programs, not per-person amounts
- School district funds go to the districts, not to individual students
- New York’s $462 million was a separate negotiation with the NY AG
- There is overlap in the defendants (JUUL and Altria contributed to multiple settlements)
- Case Management Order 23 (July 9, 2024) referenced resolution of Altria’s remaining claims
JUUL’s Product Design: How the Science Supported Liability
Understanding the product’s design is essential to understanding the legal theories.
Nicotine salt technology:
Conventional cigarette smoke and most prior e-cigarettes deliver nicotine in “freebase” form. At high concentrations, freebase nicotine causes significant throat irritation — a natural limiting mechanism. JUUL’s innovation was converting nicotine to a salt form using propionic acid, which dramatically reduced the harshness at high nicotine concentrations.
Effect: A user could inhale the nicotine equivalent of several cigarettes without the normal sensory cues warning them to stop.
The youth targeting evidence:
JUUL’s internal documents — obtained through MDL discovery — became central to the litigation. Plaintiff attorneys argued these documents showed:
- JUUL specifically studied youth appeal in product development
- The company’s early marketing campaigns (including the “JUUL Starter” social media rollout in 2015) targeted young adults and teens
- JUUL employees expressed awareness that the product was reaching minors
- Altria’s investment came with knowledge of JUUL’s youth-reaching market penetration
These internal documents formed a critical part of what allowed plaintiffs to argue that JUUL’s conduct was not just negligent but potentially willful — supporting claims for punitive damages in some states.
Legal Theories in the JUUL Litigation
Product liability — design defect: The nicotine salt delivery system, with its high-nicotine, low-irritation profile, was allegedly designed in a manner that made the product unreasonably addictive.
Product liability — failure to warn: JUUL did not adequately disclose to users (particularly young users) the extraordinary nicotine concentration in its pods or the speed at which addiction could develop.
Negligent marketing: JUUL’s social media campaigns, use of youth influencers, and flavor selection (mango, mint, cucumber) were allegedly designed to attract underage users despite knowing the product was highly addictive.
Consumer protection / UDAP violations: Each state attorney general case rested substantially on state consumer protection laws. These claims do not require individual physical injury — they address deceptive trade practices toward consumers.
RICO claims (in some cases): Some plaintiffs alleged a pattern of racketeering activity by JUUL and Altria under the federal RICO statute, pointing to a coordinated scheme to market addictive products to youth while obscuring the risks.
Who May Still Have a Viable Claim in 2026?
Most individual injury claims resolved through the December 2022 settlement. However, certain individuals may have been excluded or may have opted out:
Potential remaining claimants:
- Individuals who did not receive notice of the settlement and did not file by the applicable deadline
- Opt-out plaintiffs who rejected the settlement terms and are pursuing individual litigation
- Individuals with unusually severe injuries (significant pulmonary disease, severe nicotine-related cardiovascular events) who may have had claims worth more than settlement program amounts
- Late-diagnosed conditions attributable to JUUL use
Statute of limitations for minors — critical rule:
In most states, if you were a minor when harmed, the SOL clock did not start until you turned 18. If you are now an adult who used JUUL as a teen:
- California: 2 years from age 18
- New York: 3 years from age 18
- Texas: 2 years from age 18 (with limited exceptions)
- Florida: 2 years from age 18
If you turned 18 in 2022 and live in a 2-year SOL state, your window may have closed. Act immediately — consult an attorney to determine your exact deadline.
Scenario: A Family’s Experience with JUUL Addiction
The situation: A 24-year-old woman in Illinois who used JUUL starting at age 14 (2016) while in 8th grade. A classmate brought the product to school. She became addicted within weeks, continuing through high school. By age 18, she had sought nicotine addiction counseling. At 20, she was diagnosed with a chronic respiratory condition by a pulmonologist who noted her prior heavy vaping history.
Legal considerations:
- Illinois SOL for personal injury: 2 years from age 18 (i.e., age 20)
- Her pulmonary diagnosis came at age 20, potentially extending the SOL under the discovery rule
- If she did not participate in the 2022–2023 settlement, she should consult an attorney immediately
- Pulmonology records documenting prior e-cigarette use, counseling records showing addiction treatment, and any school discipline records are key evidence
- Illinois has a 5-year SOL under the Biometric Information Privacy Act (BIPA), but BIPA applies to biometric data collection, not nicotine addiction claims — her claim falls under the 2-year personal injury SOL
This scenario illustrates that late-diagnosed physical harms can create viable claims even years after initial product use, particularly where the discovery rule applies.
The Role of School Districts and Public Health
The $1.2 billion school district settlement addressed a distinct category of harm: schools bore significant costs in combating youth vaping. These included:
- Increased school counseling and enforcement costs
- Installation of vaping detectors in school bathrooms
- Development and delivery of anti-vaping curriculum
- Student discipline and suspension costs related to JUUL use
The settlement funds are not distributed to individual students or their families. They are paid to school districts for remediation and prevention programs. However, school discipline records related to JUUL are potentially useful as corroborating evidence in individual student claims.
State Attorney General Settlements: What They Covered
The September 2022 multi-state AG settlement ($438.5M with 33 states and Puerto Rico) addressed:
- Alleged violations of consumer protection laws
- Marketing practices targeting youth
- Deceptive advertising and omission of addiction risk disclosures
- Public health costs borne by state governments
These settlement funds are allocated at each state’s discretion — typically for youth tobacco cessation programs, school-based prevention, and law enforcement of tobacco laws. These funds are not compensation to individual harmed users.
States included: (The settlement covered 33 states plus Puerto Rico. Not all 50 states participated in this agreement — some negotiated separately or as part of the December 2022 broader agreement. Check with your state AG’s office for specifics on your state’s participation.)
How to Determine if You Have a Remaining Claim
Step 1: Determine whether you were part of the settled class.
If you received a settlement notice and did not opt out, you likely released your claims as part of the December 2022 agreement. If you received no notice, you may not have been included.
Step 2: Assess your injury.
Conditions that may support individual claims:
- Diagnosed nicotine addiction with treatment history
- Pulmonary conditions (EVALI — e-cigarette or vaping product use-associated lung injury — or chronic respiratory disease)
- Cardiovascular events in young users potentially linked to nicotine toxicity
- Significant mental health sequelae attributable to nicotine dependence
Step 3: Calculate your SOL deadline.
If you were a minor user who is now 18 or older, calculate: age at harm + state SOL = deadline. Do not wait.
Step 4: Consult a mass tort attorney.
Many firms that handled the original MDL 2913 work continue to represent individual clients on remaining claims or unresolved issues. Initial consultations are free.
FDA’s Actions Against JUUL — Background Context
In June 2022, FDA issued a marketing denial order (MDO) for JUUL’s PMTA (Premarket Tobacco Product Application), meaning FDA determined JUUL had not demonstrated its products met the “appropriate for the protection of public health” standard. FDA’s stated concern centered on toxicological data gaps, not youth appeal per se.
JUUL obtained a federal court stay of the MDO while it pursued administrative review. As of 2026, JUUL’s regulatory situation remains unresolved — the company cannot freely market its products in the U.S. without FDA authorization.
For litigation purposes, the FDA MDO is significant because it supports the argument that JUUL’s products posed public health risks that were not adequately characterized or disclosed.
What to Do Right Now
-
Document your JUUL use. Write down: age when you started, how long you used, what products and flavors, how you obtained them.
-
Gather medical records. Any records documenting nicotine addiction diagnosis, addiction treatment, pulmonary testing, or mental health counseling related to nicotine dependence.
-
Check your state’s SOL for minors. If you were a minor user who is now 18+, calculate your deadline.
-
Determine whether you were part of the settled class. If you received settlement notices, review what claims you released.
-
Consult a mass tort attorney immediately. Most will evaluate your case for free. Provide them with your use history, medical records, and any settlement notices you received.
-
If you are a parent: Gather your child’s school records, counseling records, and medical records documenting JUUL-related harms.
Related Mass Tort Litigation
- GLP-1 NAION Vision Loss Lawsuit MDL 3163 2026
- 23andMe Data Breach Class Action Lawsuit 2026
- AT&T Data Breach Lawsuit MDL 3114 2026
- Hawaii Maui Wildfire Lawsuit 2026
- Exactech Knee Hip Recall Lawsuit MDL 3044 2026
This article is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for advice specific to your situation. Laws vary by state. Information current as of May 2026; litigation is ongoing and circumstances may change.
What is MDL 2913?
MDL 2913 is 'In re: JUUL Labs, Inc., Marketing, Sales Practices, and Products Liability Litigation,' Case No. 3:19-md-02913, pending in the Northern District of California before Judge William H. Orrick. It consolidates thousands of claims against JUUL Labs and Altria for allegedly targeting minors with addictive nicotine products.
How much has JUUL paid in settlements?
Multiple separate settlement agreements have been reached: approximately $1.7 billion aggregate settlement (December 2022, covering roughly 10,000 personal injury, consumer, and government claims); approximately $438.5 million settlement with 33 state attorneys general plus Puerto Rico (September 2022); approximately $1.2 billion school district settlement covering approximately 1,600 districts (April 2023); and a separate $462 million settlement with the New York Attorney General. These are distinct agreements.
Is the MDL still active in 2026?
Yes, to a limited extent. The vast majority of claims resolved through the major 2022–2023 settlement rounds. Case Management Order 23 (July 9, 2024) noted that the Altria settlement resolved most remaining claims. However, some opt-out plaintiffs continue individual litigation as of 2026.
Why is Altria named as a defendant?
Altria Group (formerly the parent of Philip Morris USA) acquired approximately 35% of JUUL Labs in December 2018 for approximately $12.8 billion. Plaintiffs allege Altria leveraged its tobacco industry marketing expertise to support JUUL's youth-targeting campaigns and provided resources that facilitated JUUL's rapid market penetration.
Who can file a claim?
Individuals who used JUUL products as minors (under 18) and developed nicotine addiction, or parents/guardians of such minors, may have claims. Exact eligibility depends on the settlement category and timing. Consult an attorney to determine whether you qualify under any remaining claims process.
Why was JUUL's nicotine delivery so dangerous for teens?
JUUL used a nicotine salt formulation with propionic acid that enabled delivery of extremely high nicotine concentrations (approximately 59 mg/mL) with minimal throat irritation. This is equivalent to about one pack of cigarettes per pod. Adolescent brains are significantly more vulnerable to nicotine addiction than adult brains. The high-nicotine, low-irritation delivery system accelerated dependence while reducing users' ability to self-limit intake.
What harms can be compensated?
Potential compensable harms include: nicotine dependence and addiction treatment costs; physical health effects (pulmonary, cardiovascular); emotional distress and mental health impacts; academic impacts; and, in some states, punitive damages if JUUL's conduct is found to meet the legal threshold for willful or reckless misconduct.
What is the statute of limitations for minors?
In many states, statutes of limitations for minors are tolled (paused) until the minor reaches age 18. After reaching majority, the applicable SOL period begins. If you were under 18 when using JUUL and are now an adult, check whether your deadline has passed — consult an attorney promptly.
What evidence is needed to support a claim?
Helpful evidence includes: receipts or records of JUUL product purchases; medical or counseling records documenting nicotine addiction or treatment; school records showing JUUL-related discipline or counseling; documentation of the minor's age during use; and records of any health effects (pulmonary symptoms, cardiovascular issues).
What did the FDA do about JUUL?
In June 2022, FDA issued a marketing denial order (MDO) for JUUL products, concluding JUUL's PMTA application had insufficient toxicological evidence. A federal court stayed the MDO pending administrative review. JUUL's regulatory path remains uncertain, but the practical effect was to severely constrain the company's U.S. operations.
Do attorneys charge upfront fees?
No. Mass tort attorneys handle these cases on contingency: 33%–40% of any recovery, paid only upon successful resolution. Initial consultations are free. You owe nothing if there is no recovery.
Can parents file claims on behalf of their children?
Yes. Parents or legal guardians can file claims as next friends on behalf of minor children who suffered harm. If the child is now an adult, they can file in their own name.
관련 글
GLP-1 NAION Vision Loss Lawsuit MDL 3163: Ozempic, Wegovy & Trulicity Eye Injury Claims 2026
AT&T Data Breach Lawsuit MDL 3114: $177M Settlement & Claims Guide 2026
Hawaii Maui Wildfire Lawsuit 2026: $4.037B Settlement, Eligibility & How to File
Asbestos Trust Fund Claims for US Navy Veterans With Mesothelioma: 2026 Guide
Valsartan NDMA Blood Pressure Drug Cancer Lawsuit MDL 2875: 2026 Claimant Guide
